Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor F1 |
| Gene Name | ADGRF1 |
| Uniprot | Q5T601 (Human); Q8VEC3 (Mouse) |
| Synonym | PGR19; GPR110; KPG_012; hGPCR36; G protein-coupled receptor 110; G protein-coupled receptor PGR19; G-protein coupled receptor KPG_012; probable G-protein coupled receptor 110; seven transmembrane helix receptor |
| Background | ADGRF1, also known as G protein-coupled receptor 110 (GPR110) or G protein-coupled receptor PGR19, is a protein encoded by the human GPR110 gene. As a member of the G-protein coupled receptor 2 family, it is characterized by an extended extracellular region with a variable number of N-terminal protein modules coupled to a TM7 region via a domain known as the GPCR-Autoproteolysis Inducing (GAIN) domain. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX316 | NativeExtract™ Human ADGRF1 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MP0436X | MemDX™ Membrane Protein Human ADGRF1 (Adhesion G protein-coupled receptor F1) with GST-tag for Antibody Discovery | Wheat germ cell-free | Full length | N/A |
| MP0435X | MemDX™ Membrane Protein Human ADGRF1 (Adhesion G protein-coupled receptor F1) without tag for Antibody Discovery | Wheat germ cell-free | Full length | Liposome |
| Please for more products or customization | ||||
Wi***am: Creative Biolabs’ ADGRF1 protein exhibits >95% purity via SDS-PAGE, ideal for crystallization trials.
16/Apr/2023
H***y: Exceptional technical support and adherence to tight deadlines set this service apart.
05/Nov/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
ADGRF1 Knockdown for Oncological Indications
Creative Biolabs offers ADGRF1 knockdown services for oncological indications. ADGRF1, an adhesion G protein-coupled receptor, exhibits aberrant activation in multiple solid tumors. Targeted genome editing enables precise disruption of the ADGRF1 coding sequence, thereby attenuating tumorigenic signaling cascades. Preclinical models demonstrate that ADGRF1 knockout via lipid nanoparticle-delivered ribonucleoprotein (RNP) complexes reduces metastatic potential in triple-negative breast cancer by >60%. Creative Biolabs’ proprietary RNA libraries and in vivo delivery optimization platforms can accelerate the translation of such therapeutic strategies.
ADGRF1 Dominant-Negative Mutant Delivery
Creative Biolabs offers ADGRF1 dominant-negative mutant delivery services. Adeno-associated virus (AAV) vectors engineered with tissue-specific promoters enable selective ADGRF1 modulation in neurological disorders. For instance, intracranial delivery of AAV9 vectors expressing a dominant-negative ADGRF1 truncation mutant (ΔC-terminal) in Parkinsonian rodent models suppresses hyperactive dopaminergic signaling, restoring motor coordination by 48%. Creative Biolabs’ capsid engineering expertise ensures enhanced blood-brain barrier penetration for CNS applications.
RNAi Therapeutics for ADGRF1 Overexpression Syndromes
Creative Biolabs offers RNAi therapeutics services for ADGRF1 overexpression syndromes. Small interfering RNA (siRNA) conjugates targeting ADGRF1 exon 5 significantly reduce receptor density in inflammatory bowel disease models. siRNA administered subcutaneously achieves 85% hepatic ADGRF1 mRNA silencing, mitigating fibrosis progression in preclinical NASH cohorts. Creative Biolabs’ in vitro screening platforms validate siRNA efficacy across primary human hepatocytes, ensuring clinical translatability.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRF1 cell therapy. Please for more services.
ADGRF1-Engineered CAR-T Cells
Creative Biolabs offers ADGRF1-engineered CAR-T cells services. Chimeric antigen receptor (CAR) T-cells transduced with ADGRF1-specific single-chain variable fragments (scFvs) demonstrate potent cytotoxicity against glioblastoma stem cells in vitro. Second-generation constructs incorporating 4-1BB costimulatory domains enhance T-cell persistence, achieving 92% tumor regression in orthotopic xenografts. Creative Biolabs’ lentiviral vector production services ensure high-titer, GMP-compliant CAR-T cell reagents.
iPSC-Derived ADGRF1+ Neural Progenitors
Creative Biolabs offers iPSC-derived ADGRF1+ neural progenitors development services. Directed differentiation of iPSCs into ADGRF1-expressing dopaminergic neurons offers promise for neurodegenerative repair. ADGRF1 upregulation in midbrain organoids increases tyrosine hydroxylase+ cells by 3.2-fold, enhancing graft survival in Parkinson’s disease models. Creative Biolabs provides genome-wide libraries and iPSC characterization assays to streamline therapeutic cell line development.
Ex Vivo ADGRF1-Modified Macrophages
Creative Biolabs offers ex vivo ADGRF1-modified macrophages services. Lentiviral overexpression of ADGRF1 shRNA in primary human macrophages reprograms M1-to-M2 polarization, reducing IL-6 secretion by 74% in rheumatoid arthritis synovia co-cultures. Creative Biolabs’ electroporation-based gene delivery systems achieve >90% transfection efficiency in refractory immune cells. Explore our portfolio of polarization biomarkers and functional assays to quantify therapeutic efficacy.
Creative Biolabs delivers end-to-end solutions for ADGRF1-focused therapeutic development. Our multidisciplinary team offers complimentary feasibility assessments to de-risk preclinical milestones. Please feel free to to secure a project consultation slot and accelerate your pipeline’s transition to IND-enabling studies.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
